Patent · US Active

KIF18A inhibitors

US12054476B2 · kind B2 · utility

0Cited by

44References

31Claims

0Family size

Assignee

AMGEN INC. · US

Inventors

Nuria A. Tamayo · Newbury Park, US
Abhisek Banerjee · Narayanpur, IN
James Brown · Moorpark, US
Michael J. Frohn · Thousand Oaks, US
Jian Chen · Camarillo, US
Kexue Li · Newbury Park, US
Qingyian Liu · Camarillo, US
Jonathan D. Low · Thousand Oaks, US
Vu Van Ma · Simi Valley, US
Liping H. Pettus · Thousand Oaks, US
Mary Walton · Pacifica, US
Ana Elena Minatti · Santa Monica, US
Matthew P. Bourbeau · Calabasas, US
Lei Jia · Palo Alto, US

Key dates

Filing date	Dec 14, 2021
Grant date	Aug 6, 2024
Priority date	—
Expiry date	Jan 20, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D491/107
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.